Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 388-394

  Yuan, Wei ^a   Xia, Guimin ^b   Zhao, Chen ^a   Sui, Chenguang ^a   Ma, Jie ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Anti idiotypic antibody; Fusion protein; Ovarian cancer; Tuftsin

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CA 125 ANTIGEN; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUFTSIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; FEMALE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CA-125 ANTIGEN; CANCER VACCINES; FEMALE; MACROPHAGE ACTIVATION; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; TUFTSIN;

ANIMALIA; MUS;

EID: 84855662184     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.643     Document Type: Article

References (28)

1. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB and Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337, 1981. (Pubitemid 12235035)
2. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC Jr: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99: 267-277, 2005. (Pubitemid 41502830)
3. Bast RC Jr, Siegal FP, Runowicz C, Klug TL, Zurawski VR Jr, Schonholz D, Cohen CJ and Knapp RC: Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 22: 115-120, 1985. (Pubitemid 15048777)
4. Ma J, Zhou L and Wang D: The functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response. Cancer Sci 93: 78-84, 2002. (Pubitemid 34144715)
5. Chura JC, Van Iseghem K, Downs LS, Carson LF and Judson PL: Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107: 326-330, 2007. (Pubitemid 47575735)
6. Durrant LG, Maxwell-Armstrong C, Budkley D, Amin S, Robins RA, Carmichael J and Scholefield JH: A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 6: 422-430, 2000. (Pubitemid 30111459)
7. Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S and Ioannides CG: Fine specificity of high molecular weight-melanoma associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 64: 5481-5488, 2004.
8. Li A, Li Z, Wang Y, Zhang Y and Ma J: Construction and expression of a single chain antibody mimicking human ovarian cancer antigen CA125. Cell Mol Immunol 3: 59-62, 2006.
9. Qin Y, Wang XH, Cui HL, Cheung YK, Hu MH, Zhu SG and Xie Y: Human papillomavirus type 16 E7 peptide linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecol Oncol 96: 475-483, 2005. (Pubitemid 40127151)
10. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, Silva AD, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S, Wimberger P, Kimmig R and Baeuerle PA: Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65: 2882-2889, 2005. (Pubitemid 40490092)
11. Schwegler C, Dorn-Beineke A, Nittka S, Stocking C and Neumaier M: Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice. Cancer Res 65: 1925-1933, 2005. (Pubitemid 40478622)
12. Ma J, Zheng Li and Luo D: Single chain antibody vaccination in mice against human ovarian cancer enhanced by microspheres and cytokines. J Drug Targeting 11: 169-176, 2003. (Pubitemid 37236330)
13. Chu DZJ and Nishioka K: Tuftsin increases survival in murine peritoneal carcinomatosis. J Biological Response Modifiers 9: 264-267, 1990. (Pubitemid 20138589)
14. Najjar VA and Linehan L: The antineoplastic effects of tuftsin and tuftsinyltuftsin on B16/5B melanoma and L1210 cells. Ann NY Acad Sci 419: 261-267, 1983. (Pubitemid 14170166)
15. Fridkin M and Najjar VA: Tuftsin: its chemistry, biology, and physiological function. Crit Rev Biochem Mol Biol 24: 1-40, 1989.
16. Ciaccio C, Gambacurta A, Sanctis G, Spagnolo D, Sakarikou NC, Petrella G and Coletta M: rhEPO (recombinant human eosinophil peroxidase): expression in Pichia pastoris and biochemical characterization. J Biochem 395: 295-301, 2006.
17. Ma J, Luo D and Qi W: Antitumor effect of the idiotypic cascade induced by an antibody encapsulated in poly(d,l-lactide-co-glycolide) microspheres. Cancer Sci 92: 1110-1115, 2001. (Pubitemid 33041180)
18. Shao BM, Dai H, Xu W, Lin ZB and Gao XM: Immune receptors for polysaccharides from Ganoderma lucidum. Biochem Biophys Res Commun 323: 133-141, 2004. (Pubitemid 39200660)
19. Thorvaldson L and Sandler S: Factors influencing the regulation of cytokine balance during islet transplantation in mice. Transpl Immunol 20: 186-194, 2009.
20. Mu X, Kong N, Chen W, Zhang T, Shen M and Yan W: High-level expression, purification, and characterization of recombinant human basic fibroblast growth factor in Pichia pastoris. Protein Expr Purif 59: 282-288, 2008.
21. Gottlieb P, Stabinsky Y, Hiller Y, Beretz A, Hazum E, Tzehoval E, Feldman M, Segal S, Zakuth V and Spirer Z: Tuftsin receptors. Ann NY Acad Sci 419: 93-106, 1983. (Pubitemid 14170149)
22. Dhawan P, Nath I and Rao DN: Polytuftsin: its possible effects and mechanism during macrophage activation. Immunol Lett 46: 177-182, 1995.
23. Wang E, Selleri S and Marincola FM: The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. Clin Cancer Res 13: 7228-7231, 2007.
24. Mosquera LA, Card KF, Price-Schiavi SA, Belmont HJ, Liu B, Builes J, Zhu X, Chavaillaz P, Lee Y, Jiao J, Francis JL, Amirkhosravi A, Wong RL and Wong HC: In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J Immunol 174: 4381-4388, 2005. (Pubitemid 40396021)
25. Ivanov BB, Meshcheryakova EA, Andronova TM and Ivanov VT: Dituftsin and polytuftsin induce an anti-peptide IgG response to non-immunogenic peptides in mice. Immunol Invest 23: 201-212, 1994. (Pubitemid 24162041)
26. Siemion IZ and Kluczyk A: Tuftsin: on the 30-year anniversary of Victor Najjar's discovery. Peptides 20: 645-674, 1999. (Pubitemid 29425896)
27. Kriegel MA, Adam-Klages S, Gabler C, Blank N, Schiller M, Scheidig C, Kalden JR and Lorenz HM: Anti-HLA-DR-triggered monocytes mediate in vitro T cell anergy. Int Immunol 20: 601-613, 2008. (Pubitemid 351426052)
28. Zhu J, Ji Z, Wang J, Sun R, Zhang X, Gao Y, Sun H, Liu Y, Wang Z, Li A, Ma J, Wang T, Jia G and Gu Y: Tumor-inhibitory effect and immunomodulatory activity of Fullerol C60(OH)x. Small 4: 1168-1175, 2008.